GlassScriptPhysician profile
John P Wilkins
NPI 1689082539
$1,911.37
in general payments reported to CMS, 2019-2025
29 companies · $63.03 in 2025
The $63.03 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $300 · 2021: $312 · 2022: $176 · 2023: $385 · 2024: $328 · 2025: $63.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.18 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $264.13 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $261.38 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $189.50 | 2019-2024 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $173.75 | 2019-2023 | Xarelto |
| Abbvie INC. | $103.94 | 2022-2024 | Vraylar |
| Amgen INC. | $88.21 | 2019-2024 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $76.91 | 2022-2023 | Bexsero, Arexvy, Shingrix |
| Pfizer INC. | $71.43 | 2021-2023 | |
| Lundbeck LLC | $67.36 | 2023-2024 | Rexulti |
| Mylan Specialty L.P. | $60.86 | 2022-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $57.25 | 2019-2023 | |
| Astellas Pharma US INC | $51.49 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $49.27 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $42.32 | 2019-2025 | Eohilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.79 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $39.66 | 2019-2021 | |
| Medtronic, INC. | $28.98 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $28.92 | 2023-2024 | Rexulti |
| Smith+Nephew, INC. | $27.29 | 2020 | |
| Merck Sharp & Dohme LLC | $25.17 | 2021 | |
| Alkermes, INC. | $24.70 | 2023 | Aristada, Lybalvi |
| Actelion Pharmaceuticals US, INC. | $21.31 | 2024 | Opsumit, Uptravi |
| Sumitomo Pharma America, INC. | $19.41 | 2024 | Gemtesa |
| Exact Sciences Corporation | $18.50 | 2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $17.85 | 2024 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $17.16 | 2023 | Seglentis |
| Neurelis, INC. | $15.99 | 2023 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $14.48 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.36 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wilkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.